RE-PHIRE (Recruiting)
A Phase 2b Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Patients with Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)
- Medicine
- AZD3427
- Population
- Heart failure
- Phase
- II
- Starting year
- 2022